Data thru May 13, 2026
HomeTrendsArticlesDrug MarketsTherapeutic ClassesManufacturersPricingContact
Back to Market Feed

NEFAZODONE HCL 200 MG TABLET

Nefazodone Hydrochloride
$1.3306per EA

Strength

200 mg/1

Manufacturer

Teva Pharmaceuticals USA Inc.

NDC

00093102506

Classification

Generic

Dosage Form

TABLET

Route

ORAL

Last Updated

4/22/2026

Active Ingredients

NEFAZODONE HYDROCHLORIDE

Approval Type

Generic (ANDA)

FDA Application

ANDA076037

On Market Since

9/16/2003

Pharmacological Classes

Serotonin Reuptake Inhibitor

Price History

1W

0.0%

1M

0.0%

3M

-6.4%

6M

-6.4%

1Y

-6.6%

3Y

+10.9%

5Y

+10.9%

All

+137.5%

Generic Alternatives

No alternatives available

No alternatives found with the same active ingredient, strength, and dosage form.

Related Drugs

Same classification

CITALOPRAM HBR 10 MG TABLET
Generic
00378623101•Mylan Pharmaceuticals Inc.
$0.0254
per EA
CITALOPRAM HBR 10 MG TABLET
Generic
00378623105•Mylan Pharmaceuticals Inc.
$0.0254
per EA
CITALOPRAM HBR 10 MG TABLET
Generic
00904608461•Major Pharmaceuticals
$0.0254
per EA
CITALOPRAM HBR 10 MG TABLET
Generic
13668000901•Torrent Pharmaceuticals Limited
$0.0254
per EA
CITALOPRAM HBR 10 MG TABLET
Generic
13668000905•Torrent Pharmaceuticals Limited
$0.0254
per EA
CITALOPRAM HBR 10 MG TABLET
Generic
13668000909•Torrent Pharmaceuticals Limited
$0.0254
per EA
CITALOPRAM HBR 10 MG TABLET
Generic
42806001901•Epic Pharma LLC
$0.0254
per EA
CITALOPRAM HBR 10 MG TABLET
Generic
42806001910•Epic Pharma LLC
$0.0254
per EA
CITALOPRAM HBR 10 MG TABLET
Generic
65862000501•Aurobindo Pharma Limited
$0.0254
per EA
CITALOPRAM HBR 10 MG TABLET
Generic
65862000505•Aurobindo Pharma Limited
$0.0254
per EA

Data Source

Pricing data sourced from the National Average Drug Acquisition Cost (NADAC) survey, published by the Centers for Medicare & Medicaid Services (CMS). Updated weekly.

Disclaimer

This site is for informational purposes only and does not constitute medical, pharmaceutical, or financial advice. NADAC prices are survey-based estimates and may not reflect actual acquisition costs at any specific pharmacy.

Navigate

HomeAboutManufacturersDrug MarketsTherapeutic ClassesTrendsArticlesPricingContact

© 2026 NADAC Intelligence. All rights reserved. Not affiliated with CMS or any government agency.

Terms of ServicePrivacy Policy